CAR-T in Subjects With Relapsed/Refractory Autoimmune Disease

NCT07193667 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

3

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Autoimmune Diseases

Interventions

DRUG: CD19 CAR-T cells were administered to patients with relapsed/refractory autoimmune diseases

Sponsor

ShenZhen Cell Valley

Collaborators

[object Object]